❖ Independent advisers committee to the US Food and Drug Administration (FDA) gave nod to the new Alzheimer’s drug - Donanemab.

❖ Donanemab is a monoclonal antibody that targets amyloid beta protein plaques in the brain.

❖ Though the therapy slows down the progression of the disease, it does not ultimately treat the disease.

❖ Alzheimer’s disease has multiple modalities and we would need various therapies.